698 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by 4WEALTH Advisors Inc.

4WEALTH Advisors Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 698 shares of the company's stock, valued at approximately $539,000.

Several other institutional investors have also recently made changes to their positions in LLY. Pennington Partners & CO. LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $448,000. Blue Rock Wealth Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $232,000. Keel Point LLC grew its holdings in shares of Eli Lilly and Company by 3.6% during the 4th quarter. Keel Point LLC now owns 3,001 shares of the company's stock worth $2,317,000 after purchasing an additional 104 shares during the period. FAS Wealth Partners Inc. raised its stake in shares of Eli Lilly and Company by 57.1% in the 4th quarter. FAS Wealth Partners Inc. now owns 8,856 shares of the company's stock valued at $6,837,000 after acquiring an additional 3,218 shares during the period. Finally, Peterson Wealth Management raised its holdings in shares of Eli Lilly and Company by 27.4% in the 4th quarter. Peterson Wealth Management now owns 4,951 shares of the company's stock valued at $3,823,000 after buying an additional 1,065 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $794.67 on Friday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm has a market cap of $753.49 billion, a price-to-earnings ratio of 67.86, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The firm's fifty day moving average price is $826.90 and its 200 day moving average price is $816.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.58 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Finally, Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a report on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,000.32.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.